Vallon Pharmaceuticals Inc Stock price
Is Vallon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Vallon Pharmaceuticals Inc Stock Analysis
Analyst Opinions
6 Analysts have issued a Vallon Pharmaceuticals Inc forecast:
Analyst Opinions
6 Analysts have issued a Vallon Pharmaceuticals Inc forecast:
Don't miss a Thing! We will send you all news about Vallon Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vallon Pharmaceuticals Inc Stock News
Company Profile
Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.
| Head office | United States |
| CEO | Dr. Hertz |
| Employees | 4 |
| Founded | 2009 |
| Website | www.gribio.com |


